Studies on mice report different things, mostly improved or maintained insulin in muscle but impaired glucose tolerance systematically or in the liver alone
Some plans may cover GLP-1 drugs for diabetes but not for weight loss
Cedillo-Flores et al., 2025)
She really knows how to make your eyes pop
Indeed, CDER Acting Director Michael Davis reinforced the policy point publicly on X, emphasizing that compounded GLP1 products are not FDAapproved and have not undergone the rigorous review for safety, efficacy, and manufacturing quality that is required for drugs approved through the new drug application (NDA) or abbreviated new drug application (ANDA) pathways.[3] This is now the third major set of warning letters in less than a year with the majority aimed at telehealth marketing of compounded GLP-1 products: September 2025: roughly 80 warning letters and 40 untitled letters March 2026: 30 warning letters June 2026: 25 warning letters The Claims FDA Is Targeting As in earlier rounds, the June 2026 letters appear highly standardized and focus on consumerfacing promotion of compounded GLP-1 products
Some evidence suggests hyperglycemic state decreases GLP-1 secretion in T2DM [39, 40]
01127-3/asset/cb71a1fc-b829-4644-a5d6-f1f235f450bf/main.assets/gr2_lrg.jpg)
